Acquisition of Lisata Therapeutics Delayed Again; Buyer Offers No Assurance
LSTA has more than doubled off its 52-week low of $1.81 on elevated volume (18× avg).
Summary
Kuva Labs has once again postponed its tender offer to acquire Lisata Therapeutics, which was planned for June 1st, and explicitly stated there is no assurance the offer will commence at all. This follows an 8-K filed today and marks the latest in a series of negative developments for the acquisition, which was initially announced in March. The deal previously faced a delay in April and a reduction in the acquisition price in late May. Given Lisata's prior 'going concern' warning in May, citing acquisition delays and declining cash, the continued uncertainty and potential failure of this deal would have severe implications for the company's ability to continue operations.
At the time of this announcement, LSTA was trading at $4.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $1.81 to $5.07. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.